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Introduction
Globally, 376 million curable sexually transmitted 
infections (STIs) were recorded in 2016 among people 
aged 15–49 years.1 Although the concerted focus on HIV 
infection has led to a substantial decline in HIV incidence 
in many countries, STI programmes have not been 
e!ective and the prevalence of STIs globally is increasing.2 
Adolescents and young people, especially young women, 
are at particularly high risk of STIs, with higher prevalence 
than that in older age groups observed in east and 
southern Africa.3
Over the past three decades, syndromic management of 
STIs has been implemented in resource-limited settings 
due to lack of laboratory capacity. However, syndromic 
management has consistently been shown to have very 
poor sensitivity and specificity, leading to considerable 
levels of both underdiagnosis and overtreatment.4 Crucially, 
many curable STIs are asymptomatic, but syndromic 
management requires the presence of symptoms. 
Therefore, in settings where diagnostic testing is not 
available, participants with asymptomatic STIs will not 
receive treatment. The WHO 2016–21 strategy on STIs 
notes that “investment in point-of-care test development 
will generate future savings by lowering STI diagnostic 
and screening costs, and improving case management and 
detection of asymptomatic STI, thus contributing to lower 
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Summary
Background The prevalence of sexually transmitted infections (STIs) among youth is high in sub-Saharan Africa. 
We investigated the uptake of testing for and prevalence of Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae 
(gonorrhoea) infections among youth in community-based settings in Zimbabwe, and explored the facilitators and 
barriers to testing.
Methods This study was nested within a cluster randomised trial of community-based delivery of integrated HIV and 
sexual and reproductive health services for youth aged 16–24 years. Chlamydia and gonorrhoea testing via urine 
samples using the Xpert CT/NG test was o!ered in the four intervention clusters in Harare, Zimbabwe. Factors 
associated with testing uptake were investigated in a subset of participants (n=257) using hierarchical multivariate 
logistic regression. In-depth interviews with a separate purposively selected sample (n=26) explored facilitators and 
barriers to STI testing and partner notification and were analysed using thematic analysis.
Findings Between June 1, 2019, and Jan 31, 2020, there were 6200 attendances by 4440 participants (78·2% women, 
21·8% men) median age 20·3 (IQR 17·9–22·8) years. 1478 participants had 1501 tests done, and 248 tests were 
positive and 1253 tests were negative for chlamydia or gonorrhoea, or both. STI test uptake was 33·3% (95% CI 
31·9–34·7), increasing from 11·7% in June, 2019, to 37·1% in January, 2020. The prevalence of chlamydia or 
gonorrhoea, or both, was 16·5% (95% CI 14·7–18·5; 248 of 1501), with only seven participants (3%) showing 
symptoms. The overall yield of testing was 4·0% (95% CI 3·5–4·5; 248 of 6200). Uptake was associated with having 
symptoms (adjusted odds ratio [OR] 14·8, 95% CI 1·66–132·07) and negatively associated with being single (adjusted 
OR 0·33, 95% CI 0·13–0·84) or having a boyfriend or girlfriend (adjusted OR 0·19, 95% CI 0·087–0·43) compared 
with being married, and being a student compared with being employed (adjusted OR 0·26, 95% CI 0·10–0·68). 
Perceived risk and symptoms of STIs were motivators for testing whereas misinformation, anticipated stigma, and 
concern about confidentiality were barriers.
Interpretation The prevalence of chlamydia or gonorrhoea, or both, was high among youth but only a minority were 
symptomatic. Therefore most infections would remain untreated without access to STI testing. Provision of education, 
counselling, and confidentiality are essential to improve uptake and acceptability of STI testing.
Funding Wellcome Trust.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
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STI burdens”.5 Over the past decade, simpler diagnostic 
platforms for STIs that do not require sophisticated 
laboratory infrastructure have been developed. However, 
data on uptake and acceptability of testing if o!ered to 
asymptomatic individuals, particularly among youth,  are 
sparse.
Young people experience multiple barriers to accessing 
sexual and reproductive health (SRH) services. In add-
ition to a lack of availability or knowledge of services, 
costs and long waiting times as a barrier to access, 
perceived judgmental attitudes of health-care providers, 
and concerns surrounding confidentiality result in low 
uptake of services.6,7 Therefore, STI testing strategies will 
need to account for and address these factors to facilitate 
optimum uptake and acceptability.
The aims of this study were to investigate the preva-
lence of Chlamydia trachomatis (chlamydia) and Neisseria 
gonorrhoeae (gonorrhoea), and uptake and yield of testing 
o!ered as part of an integrated package of SRH and HIV 
services in community-based settings to youth aged 
16–24 years in Harare, Zimbabwe, and to explore 
facilitators and barriers to uptake of chlamydia and 
gonorrhoea testing.
Methods 
Study design and participants
This study was nested within the CHIEDZA trial 
(Community based interventions to improve HIV 
outcomes in youth: a cluster randomised trial in 
Zimbabwe; NCT03719521), a cluster randomised trial 
invest igating the e!ect of an integrated package of HIV 
and SRH services for youth in community-based settings 
on population level HIV prevalence and other health 
outcomes. The two-arm trial is being done in 24 clusters in 
three provinces (Harare, Mashonaland East, and Bulawayo), 
with each province randomised to four intervention and 
four standard of care (routine, existing services) clusters 
(1:1). A cluster is a geogra phically demarcated area 
containing a primary health-care clinic and a community 
centre from which services are delivered.
Individuals aged 16–24 years living within an 
intervention cluster are eligible to receive a package of 
services including HIV testing, HIV treatment and 
adherence support, contraception, pregnancy testing, 
syndromic management of STIs, menstrual health 
information and products, condoms, and general health 
counselling. Treatment of STIs and HIV is delivered 
according to national guidelines. In each cluster, services 
are delivered once weekly (on the same day each week) by 
a team of nurses, community health workers, youth 
workers, and a counsellor, and all services are o!ered 
free of cost. The services are configured to be youth-
friendly and to ensure confidentiality. The services are 
provided from 1100 h to 1900 h and operate on an open 
access basis with no previous appointments required. 
There is no limit to the number of times an individual 
can access the service over time. The present study was 
done in the four intervention clusters in Harare.
Research in context
Evidence before this study
We searched MEDLINE for articles published before 
July 30, 2020, with no language restrictions, with the search 
terms (variations on and synonyms of) “sexually transmitted 
infections” AND “testing” AND “uptake” AND “youth” AND 
“sub-Saharan Africa”. Of the 619 articles identified by this 
search, there were no studies that assessed uptake of sexually 
transmitted infection (STI) testing among youth when o!ered 
universally in a community-based setting in sub-Saharan Africa. 
A study published in 2020, investigated self-reported “lifetime 
STI testing  among urban refugee and displaced youth living in 
informal settlements in Kampala, Uganda. Among young 
women, predictors of lifetime STI testing were older age, lower 
sexual activity and pregnancy stigma, and lower food 
insecurity. Except for older age, predictors were di!erent for 
young men including higher self-e"cacy in condom use, and 
increased sexual activity and pregnancy stigma. However, 
lifetime STI testing was self-reported and thus subject to bias 
and misclassification.
Added value of this study
This study is an important addition to a very sparse literature. 
To our knowledge, it is the first study to implement testing for 
Chlamydia trachomatis (chlamydia) and Neisseria gonorrhoeae 
(gonorrhoea) infections in adolescents in a community-based 
setting in sub-Saharan Africa and to investigate the cascade 
from testing to treatment including partner notification. 
Crucially, uptake of testing and associated factors was assessed 
after testing was actually o!ered to youth. Additionally, 
we found a high prevalence of chlamydia and gonorrhoea yet 
only a small minority reported the presence of symptoms. 
The qualitative data from in-depth interviews further 
contextualised the barriers that youth face in accessing services 
for STIs including stigma, misinformation, and concerns 
surrounding confidentiality. We have also showed the 
di"culties associated with partner notification, and further 
research is needed to optimise this process.
Implications of all the available evidence
This study contributes towards the mounting evidence 
regarding the limitations of syndromic management and the 
need to further develop and implement point-of-care 
diagnostics in resource-limited settings. We have demonstrated 
the feasibility of a community-based model for STI testing for 
youth in resource-limited settings. Further innovative 
strategies for the delivery of STI testing and care will need to be 
developed to ensure high levels of uptake as point-of-care tests 
for STIs become more widely available.
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Ethical approval for the CHIEDZA trial including the 
STI study was obtained from the Medical Research 
Council of Zimbabwe and The London School of Hygiene 
& Tropical Medicine Ethics Committee. Regarding 
services o!ered through the CHIEDZA intervention, 
verbal consent was sought for chlamydia and gonorrhoea 
testing. Written informed consent in Shona or English 
was obtained from participants who were enrolled for the 
questionnaire and for qualitative interviews. The protocol 
for the CHIEDZA trial has been previously published.
Procedures
All individuals accessing CHIEDZA services were non-
selectively o!ered confidential testing for chlamydia and 
gonorrhoea, regardless of whether they had symptoms. 
Those who accepted testing provided a first-catch urine 
sample which was tested within 48 h of collection 
using the GeneXpert platform (Cepheid, Sunnyvale, CA, 
USA). Participants were eligible for repeat testing after 
6 months. To maintain confidentiality, participants 
provided a pseudonym and samples were processed 
using an identification number.
All participants were given the option to pick up their 
result the following week, and those with a positive result 
were actively followed up by telephone. If uncontactable, 
repeat phone calls were made weekly for up to 2 months, 
after which a particpant was considered lost to follow-up. 
Indivi duals who reported STI symptoms at presentation 
were treated according to national guidelines for 
syndromic management. If treatment was given on 
the day of presentation, they were not actively contacted 
about a subsequent positive chlamydia and gonorrhoea 
test result. Given that the intervention team deliv ered 
services to a cluster once weekly, the shortest 
pos sible duration between testing and treatment for 
asymptomatic participants was 7 days. Partner notification 
slips were given to those who were treated for an STI, and 
all partners were o!ered presumptive treatment 
regardless of age and whether they resided in the 
intervention cluster.
Chlamydia and gonorrhoea testing uptake data were 
regularly reviewed in real-time and discussed at the 
intervention team’s monthly debrief meetings. During 
the course of the study, the intervention team underwent 
further training on STIs and written Information, 
Education and Communication material for participants 
was developed to enhance uptake of chlamydia and 
gonorrhoea testing.
Participants accessing CHIEDZA services at the 
four intervention sites in Harare between June 10 and 
July 16, 2019, were consecutively enrolled to complete an 
interviewer-administered questionnaire to under stand 
Figure !: Study profile
*Reasons for lack of uptake documented from Sept 3, 2019, onwards. †23 participants tested twice during the study period.
7 treated the same day 548 collected results
1253 negative tests for chlamydia
and gonorrhoea in
1237 participants
109 gave correct contact details
248 positive tests for chlamydia or
gonorrhoea or both in
246 participants
132 gave incorrect details or no
contact details
71 collected results and were
treated 
61 did not collect results 
and did not receive 
treatment
87 were contacted and attended
for treatment
22 were contacted but did 
not attend for
treatment
1501 tests for chlamydia and gonorrhoea in 1478 participants†
6200 CHIEDZA attendances from 4440 participants
 4699 attendances did not result in a test
1740 no reason available* 
1608 did not wish to be tested
317 self-perceived lack of risk
98 menstruating
867 no sexual debut
69 unable to provide urine sample
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factors associated with uptake of chlamydia and 
gonorrhoea testing. The questionnaire recorded socio-
demographic and sexual behaviour data, and included a 
mixture of open-ended and closed-ended questions to 
assess knowledge of STIs and to solicit opinions about STI 
service delivery including partner notification.
A separate purposively selected sample was also 
recruited to participate in in-depth interviews to 
explore understanding of STIs and perceived facili tators 
and barriers to chlamydia and gonorrhoea testing. 
Partici pants were selected to provide roughly equal 
repre sentation of men and women and those who 
accepted and declined chlamydia and gonorrhoea 
testing. Interviews were done by a trained interviewer 
(not involved in service delivery) at a secluded spot 
outside the community centre, in either Shona or 
English depending on participant preference. Interviews 
were done after a participant had completed their 
consultation with a health worker and were continued 
until data saturation was achieved. All interviews were 
audio-recorded and translated and transcribed by the 
interviewer.
The primary outcome of this study was uptake of STI 
testing. Secondary outcomes included prevalence of 
chlamydia and gonorrhoea, and yield of testing.
Statistical analysis
Sample size calculations to investigate chlamydia and 
gonorrhoea testing uptake assumed a ratio of 1:2 between 
those accepting and declining STI testing. Given the 
dearth of data on uptake of chlamydia and gonorrhoea 
testing in similar settings, this ratio was informed by the 
range of uptake reported in high-income countries8 
together with the fact that testing was o!ered within 
a package of youth-friendly services. Assuming a 
prevalence of a risk factor of 20% among those declining 
testing and a type I error rate of 5%, a sample size of 204 
(68 accepting testing) would provide 80% power to detect 
an odds ratio (OR) of 2·5.
The prevalence of chlamydia and gonorrhoea and 
uptake and yield of testing were recorded, and the 
proportion of participants with positive tests who 
received treatment, and time to treatment were 
calculated. 
Factors associated with uptake of STI testing were 
investigated using multivariate logistic regression. 
We used a hierarchical conceptual approach with three 
levels: (1) sociodemographic, (2) behavioural, and 
(3) other more proximal factors (appendix p 1).9,10 Age and 
sex were considered a priori confounders for each model. 
For level 1, all age-adjusted and sex-adjusted socio-
demographic factors that met a p value cuto! of less than 
0·10 were included in the multivariate model for level 1. 
Those factors that remained associated at less than 0·10 
became the core level 1 factors. For level 2, all core level 
1-adjusted behavioural factors that met a p value cuto! of 
less than 0·10 were included in the multivariate model 
for level 2, together with the core level 1 factors. 
Associations with level 3 factors were determined in a 
similar way. If factors that were restricted by reported 
penile–vaginal sex or sex met the p value cuto! and we 
wanted to use the factor to adjust other variables, a 
reference category was added to the variable so that there 
would be an unrestricted adjusted model. For example, 
for factors restricted to participants who reported having 
had penile–vaginal sex, a reference category of no penile–
vaginal sex was added to the variable when included in 
the adjusted model.
Qualitative data were analysed using thematic analysis 
on the basis of the following themes: facilitators and 
barriers to chlamydia and gonorrhoea testing uptake and 
facilitators and barriers to partner notification. Following 
familiarisation with data, codes were generated on the 
basis of these themes and subthemes emerging from the 
transcripts. NVivo 12 (QSR International) was used to 
assist with coding transcripts. Themes and coding were 
iteratively reviewed and refined. Data analysis was done 
with STATA version 15.0.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and accept responsibility for the decision to submit 
for publication.
Results
Between June 1, 2019, and Jan 31, 2020, there were 
6200 attendances to CHIEDZA services by 4440 young 
people who met the eligibility criteria for chlamydia and 
gonorrhoea testing. 3473 (78·2%) were women and 
967 (21·8%) were men, and the median age was 20·3 years 
(IQR 17·9–22·8). Of the 6200 attendances, 4699 (76%) 
were not tested for reasons including refusal, self-perceived 
lack of risk, menstruation, not yet sexually active, or unable 
to provide a urine sample (figure 1).
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In total, 1501 STI tests (24·2%) were done of the 
6200 attendances, in 1478 people, with 23 people tested 
twice over the study period at an interval of at least 
6 months, equating to an uptake of at least one chlamydia 
and gonorrhoea test of 33·3% (95% CI 31·9%–34·7%; 
figure 1). The uptake in men was 30·4% (294 of 967) and 
in women was 34·1% (1184 of 3473). The uptake of testing 
among eligible attendees increased over time from 11·7% 
(94 of 806) in the first month to 37·1% (287 of 773) 
in month eight (figure 2). The chlamydia and gonorrhoea 
prevalence among those tested was 16·5% (95% CI 
14·7–18·5; 248 of 1501). The prevalence of these STIs was 
lower in men than in women (30 [10%] of 300 vs 
218 [18·2%] of 1201, p=0·0010; table 1). Of the 
23 participants who underwent testing at two timepoints, 
two tested positive on both occasions and 16 tested 
negative both times. The overall yield of testing was 4.0% 
(95% CI 3·5–4·5; 248 of 6200).
Of 248 participants with a positive STI test, 165 (67%) 
were treated. Seven (3%) participants were symptomatic 
on presentation and following examinations were treated 
on the same day using syndromic treatment guidelines. 
Five (2%) were female participants with vaginal dis-
charge syndrome (three with gonorrhoea only, one with 
chlamydia only, and one with both infections), and 
two (<1%) were male participants with urethral discharge 
syndrome (one with gonorrhoea only and one with 
chlamydia only). Correct traceable contact details had 
only been provided by 109 (44%) of the 248 participants, 
and of these 87 (80%) attended for treatment. Of the 
132 participants who were uncontactable, 71 (54%) 
presented to collect results and were treated. The median 
time between testing and treatment in the 158 participants 
who were not treated at presentation was 7 days 
(IQR 7–21). Of the 1253 participants who had negative 
test results (and were therefore not contacted), 
548 (43·7%) attended to collect their results within 
two months of testing. Overall, 22 partners were treated 
through the partner notification process.
A total of 257 participants were recruited between 
June 10, and July 16, 2019, to investigate factors associated 
with uptake of chlamydia and gonorrhoea testing. 
Participants were broadly representative of those in the 
CHIEDZA study; the median age was 20 years 
(IQR 18–22) and 161 (63%) were women (table 2). 84 (33%) 
participants used condoms regularly and 80 (31%) used 
condoms at last sexual intercourse. Being a woman, older 
(age 21–24 years compared with age 16–20 years), married 
(compared with being single or having a girlfriend or 
boyfriend), employed (compared with being a student), 
having at least one sexual partner in the previous 
12 months, having current STI symptoms, not using a 
condom at last sexual intercourse and lower levels of 
reported condom use, higher levels of perceived risk of an 
STI, and having had at least one pregnancy were 
associated with uptake of testing in the unadjusted 
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STI testing uptake Unadjusted OR (95% CI) p value Adjusted OR* (95% CI) p value
Sociodemographic factors (level 1)
Age, years
16–20 37/148 (25%) 1 (ref) 0·0003 1 (ref) 0·34
21–24 51/109 (47%) 2·64 (1·55–4·48) 1·37 (0·72–2·59)
Sex
Male 24/96 (25%) 1 (ref) 0·017 1 (ref) 0·79
Female 64/161 (40%) 1·98 (1·13–3·46) 0·92 (0·47–1·78)
Occupation
Employed 18/35 (51%) 1 (ref) 0·0001 1 (ref) 0·019
Unemployed 54/127 (43%) 0·70 (0·33–1·48) 0·53 (0·22–1·26)
Student 16/95 (17%) 0·19 (0·08–0·45) 0·26 (0·10–0·68)
Education 
Post-secondary 5/20 (25%) 1 (ref) 0·50 1 (ref) 0·98
Secondary 76/221 (34%) 1·57 (0·55–4·49) 0·90 (0·26–3·12)
Primary 7/16 (44%) 2·33 (0·57–9·60) 0·84 (0·16–4·45)
Marital status
Married 41/63 (65%) 1 (ref) <0·0001 1 (ref) 0·0003
Partner 30/135 (22%) 0·15 (0·08–0·30) 0·19 (0·087–0·43)
Single 17/59 (29%) 0·22 (0·10–0·47) 0·33 (0·13–0·84)
Sexual behaviour factors (level 2)
Ever had oral sex†
No 54/176 (31%) 1 (ref) 0·077 1 (ref) 0·52
Yes 34/81 (42%) 1·63 (0·95–2·82) 1·24 (0·64–2·41)
Ever had anal sex†
No 86/248 (35%) 1 (ref) 0·45 1 (ref) 0·47
Yes 2/9 (22%) 0·54 (0·11–2·65) 0·54 (0·10–2·92)
Ever had penile–vaginal sex
No 11/77 (14%) 1 (ref) <0·0001 1 (ref) 0·099
Yes 77/180 (43%) 4·49 (2·22–9·06) 2·17 (0·86–5·45)
Age at sexual debut‡, years
>16 57/129 (44%) 1 (ref) 0·54 1 (ref) 0·32
#16 20/51 (39%) 0·81 (0·42–1·58) 1·49 (0·67–3·31)
Number of sexual partners in past 12 months§
0 12/83 (14%) 1 (ref) <0·0001 1 (ref) 0·13
1 54/106 (51%) 6·14 (2·99–12·63) 2·50 (0·91–6·87)
$2 22/68 (32%) 2·83 (1·28–6·27) 2·79 (0·97–8·03)
New sexual partner in past 3 months
No 75/208 (36%) 1 (ref) 0·21 1 (ref) 0·19
Yes 13/49 (27%) 0·64 (0·32–1·28) 0·57 (0·24–1·31)
Condom use at last sex‡
Yes 25/80 (31%) 1 (ref) 0·0056 1 (ref) 0·37
No 52/100 (52%) 2·38 (1·29–4·41) 0·66 (0·26–1·66)
Condom use‡
Always or mostly 27/84 (32%) 1 (ref) 0·0074 1 (ref) 0·37
Sometimes or rarely or never 50/96 (52%) 2·29 (1·25–4·21) 0·66 (0·27–1·64)
Money or gifts for sex
No 85/249 (34%) 1 (ref) 0·84 1 (ref) 0·89
Yes 3/8 (38%) 1·16 (0·27–4·96) 1·11 (0·23–5·37)
(Table 2 continues on next page)
wwmarital status, current STI symptoms remained 
strongly associated with accepting chlamydia and 
gonorrhoea testing (adjusted OR 14·79, 95% CI 
1·66–132·07). Having a boyfriend or girlfriend (adjusted 
OR 0·19, 95% CI 0·087–0·43) or being single (adjusted 
OR 0·33, 95% CI 0·13–0·84) compared with being 
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married, and being a student compared with being 
employed (adjusted OR 0·26, 95% CI 0·10–0·68) were 
negatively associated with chlamydia and gonorrhoea 
testing uptake.
Knowledge about STIs was highly variable. Of the 
257 participants who completed the questionnaire, 
231 (90%) knew that STIs could be prevented by condom 
use, and 217 (84%) knew that these infections could 
facilitate HIV transmission. However, 141 participants 
(55%) could not name any complications of STIs (table 3). 
Furthermore, 26 (10%) participants thought that insect 
bites and 25 (10%) thought that sharing clothes or towels 
could transmit STIs.
Regarding testing procedures, all 96 male participants 
and 154 (96%) of 161 female participants stated that they 
would prefer urine samples to a genital swab. The most 
preferred option for provision of STI testing services was 
in a community-based, non-clinical setting and only a 
minority identified schools as a venue where STI services 
should be o!ered (table 3). Additionally, 233 (91%) 
participants preferred to receive STI test results in 
person; 58 (23%) selected telephone and 43 (17%) selected 
text as options for receiving test results.
Although 166 (92%) of 180 participants said they 
would be able to contact sexual partners from the past 
3 months, only 142 (79%) said that they would inform 
them about a positive STI test result. Notably, 
92% (100 of 109) of female participants versus only 
59% (42 of 71) of  male participants said they would 
inform a partner about a positive STI result. The need to 
treat the partner for the partner’s sake (151 [84%]) and to 
prevent reinfection (65 [36%]) were the most common 
reasons noted for notifying partners. Reasons for not 
telling a partner about a positive STI result were fear of 
the partner leaving (92 [51%]), being blamed for the STI 
(27 [15%]), and risk of violence (22 [12%]). Regarding the 
referral process itself, 126 (70%) participants preferred 
notifying partners themselves (patient referral). 
However, 65 (36%) selected provider referral, whereby a 
health-care worker informs the contact directly, as an 
appropriate option for partner notification.
26 young people participated in in-depth interviews. 
Participants were aged 16–24 years (median 19), 
16 (62%) were women, and ten (38%) were men. Of 
STI testing uptake Unadjusted OR (95% CI) p value Adjusted OR* (95% CI) p value
(Continued from previous page)
Current contraception use (barrier methods excluded)‡¶
None 19/43 (44%) 1 (ref) 0·31 1 (ref) 0·94
Oral contraceptive pill 27/42 (64%) 2·27 (0·95–5·44) 0·95 (0·31–2·90)
Depot injection 3/6 (50%) 1·26 (0·23–6·98) 0·55 (0·084–3·61)
Implant 10/17 (59%) 1·80 (0·58–5·63) 0·94 (0·26–3·37)
Intrauterine contraceptive device 0/1 ·· ··
Circumcised||
Yes 8/32 (25%) 1 (ref) 0·48 1 (ref) 0·61
No 8/44 (18%) 0·67 (0·22–2·02) 0·74 (0·22–2·43)
Proximal factors (level 3)
Number of pregnancies¶
0 17/85 (20%) 1 (ref) <0·0001 1 (ref) 0·64
1 25/42 (60%) 5·88 (2·61–13·27) 1·41 (0·41–4·79)
$2 22/34 (65%) 7·33 (3·04–17·71) 0·89 (0·19–4·10)
Current STI symptoms‡
No 66/168 (39%) 1 (ref) 0·0073 1 (ref) 0·016
Yes 11/12 (92%) 17·00 (2·14–134·78) 14·79 (1·66–132·07)
Perceived STI risk
Unlikely or no risk 65/214 (30%) 1 (ref) 0·0015 1 (ref) 0·45
Very likely or likely 22/36 (61%) 3·60 (1·73–7·48) 1·33 (0·55–3·23)
Unsure 1/7 (14%) 0·38 (0·045–3·24) 0·30 (0·031–2·87)
Self-reported HIV status
Negative 85/253 (34%) 1 (ref) 0·13 1 (ref) 0·67
Positive 3/4 (75%) 5·93 (0·61–57·86) 1·68 (0·16–17·60)
Data are n/N (%), unless otherwise specified. STI=sexually transmitted infection. OR=odds ratio. *Sociodemographic factors adjusted for age, sex, occupation, and marital 
status (sociodemographic core set); sexual behavioural factors adjusted for sociodemographic core set and if ever had penile–vaginal sex; proximal factors were adjusted for 
sociodemographic core set, if ever had penile–vaginal sex, and presence of current symptoms. †Combined giving or receiving. ‡Question restricted to participants who 
reported having ever had penile–vaginal sex (n=180). §Because of evidence of collinearity “number of sexual partners in past 12 months” was not adjusted for “ever had 
penile–vaginal sex”. ¶Question restricted to female participants (n=161). ||Question restricted to male participants (n=76).
Table ": Multivariate analysis of factors a!ecting uptake of STI testing
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these, 12 had agreed to testing, 12 had declined testing, 
and two were unaware of testing being available. 
Emergent themes and supporting quotes are presented 
in the appendix (p 2).
STI testing uptake was motivated by presence of 
symptoms and potential treatment if they tested positive. 
Additionally, participants’ decision to be tested was 
driven by their perceived risk, based on their own and 
their partner’s sexual behaviour.
Stigma was a key barrier factor to uptake of STI testing. 
Many feared family and community members finding 






Genital ulcers 164 (64%)
Genital discharge 99 (39%)
Rash 99 (39%)
Groin swelling 46 (18%)
Dysuria 45 (18%)
Itch 42 (16%)
Abdominal pain 24 (9%)
Warts 15 (6%)
Weight loss 9 (4%)
Hair loss 9 (4%)
Haematuria 8 (3%)
Fever 7 (3%)
Red lips 5 (2%)





HIV or AIDS 19 (7%)
Blindness 7 (3%)
Testicular pain or swelling 11 (4%)
Miscarriage or ectopic pregnancy 5 (2%)
Death 3 (1%)
Pelvic inflammatory disease 2 (1%)
Loss of genitalia 3 (1%)
Neonatal disabilities 1 (<1%)
Unsure 141 (55%)
Modes of transmission of STIs†
Sex 256 (100%)
Infected blood 189 (74%)
Vertical 151 (59%)
Kissing 47 (18%)
Insect bite 26 (10%)
Sharing clothes or towels 25 (10%)
Shaking hands 0
Preferences for service delivery
Treatment-seeking behaviour for STI symptoms*‡
Attend clinic 170/180 (94%)
Attend pharmacy 10/180 (6%)
Wait for symptoms to resolve 2/180 (1%)
Get advice from family or friends 13/180 (7%)
Attend a traditional healer 1/180 (1%)
Consult a private doctor 2/180 (1%)




(Continued from previous column)
Preferred STI testing location*
Community-based non-clinic setting 190 (74%)
Clinic 168 (65%)
School or college 30 (12%)
Private doctor 13 (5%)
Other§ 5 (2%)
Preferred methods for receiving STI test results†
In person 233 (91%)
Phone call 58 (23%)
Short messaging service (SMS) 43 (17%)
Post 1 (<1%)
Partner notification
Reasons for not notifying partner if diagnosed with STI*‡
Partner might leave 92/180 (51%)
Accusation of infidelity 27/180 (15%)
Violence from partner 22/180 (12%)
Others might find out 18/180 (10%)
Embarrassment 16/180 (9%)
Not the index’s responsibility 5/180 (3%)
Other¶ 8/180 (4%)
Preferred methods for partner notification†‡
Referral by index 126/180 (70%)
Referral by provider 65/180 (36%)
Direct delivery of medication to partner by index 1/180 (1%)
Would not contact 15/180 (8%)




Never had sex 77/180 (43%)




Never had sex 77/180 (43%)
Data are n (%), or n/N (%) and include all answers given by participants. 
STI=sexually transmitted infection.  *Open-ended question with no options 
provided. †Closed-ended question, but responses could be elicited in more than 
one category. ‡Question restricted to participants who said they had penile–
vaginal sex (n=180). §Home-based testing, n=2; church, n=1; pharmacy, n=1; 
workplace, n=1. ¶Not able to contact partner, n=3; would not see partner again, 
n=2; might be accused of testing positive for HIV, n=1; partner might worry, n=2. 
||Closed-ended question for which response was confined to a single category.
Table #: Knowledge of STIs and preferences for STI testing
See Online for appendix
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about you” and being ostracised by their familes if found 
to be sexually active. Anticipated stigma alongside 
perceived lack of confidentiality among health-care 
workers was not only a barrier to uptake of testing, but 
influenced young people’s choice of health-care providers. 
Participants stated they would choose either “the furthest” 
hospital from them or a private clinic, so they wouldn’t 
“be recognised”. There were also miscon ceptions that 
impeded uptake of STI testing, including the belief that 
circumcision conferred complete protection from STIs, 
that menstruation precluded STI testing, and that HIV 
testing covered other STIs. Notably, there was much less 
concern about curable STIs than about HIV and absence 
of symptoms deterred participants from testing.
Participants were aware that if they had an STI, their 
partner might also have an STI and should be treated to 
protect them and to prevent reinfection. Although 
participants acknowledged a general need for honesty, 
telling partners was perceived to be a particular challenge. 
Discussion
We found a high prevalence of chlamydia and a moderate 
prevalence of gonorrhoea among youth o!ered testing in 
community-based settings, only a minority of whom had 
symptoms. One in six youth who took up testing 
tested positive for chlamydia or gonorrhoea, or both. 
Importantly, testing was not targeted at those with high 
risk behaviours or symptoms. The uptake of testing 
improved over time, and uptake and prevalence of the 
STIs was higher in female participants than in 
male participants. The prevalence of chlamydia and 
gonorrhoea was high in comparison to that reported in 
two previous systematic reviews of STI prevalence 
among women in sub-Saharan Africa.3,11 These findings 
emphasise the substantial STI epidemic in southern 
Africa and the unmet need for STI services, particularly 
among youth who consistently have a higher prevalence 
of STIs than do older age groups.4,12,13 Chlamydia was 
more prevalent than gonorrhoea in this group of mostly 
asymptomatic youth. However, in previous studies 
in Zimbabwe, gonorrhoea was more common than 
chlamydia among men and women presenting with 
urethral and vaginal discharge.14,15
The availability of simple diagnostic platforms provides 
an opportunity to move away from syndromic manage-
ment.16 The GeneXpert platform is a closed cartridge 
system that does not require sophisticated laboratory 
infrastructure or expert skills and is widely available in 
sub-Saharan Africa. Given that a single dose treatment is 
available for STIs such as chlamydia and gonorrhoea, 
point-of-care STI diagnostics paired with immediate 
treatment would have an impact on STI control.17 However, 
in addition to the high cost, the need for a continuous 
power supply and the time to result (90 min) preclude the 
use of the Xpert CT/NG platform as a true point-of-care 
test.18 In our study, the earliest available results were 
1 week post-testing, which might have resulted in lower 
treatment rates of those diagnosed with an STI.
Diagnostic testing will only be e!ective in curbing the 
STI epidemic if accessible, acceptable delivery strategies 
are developed. Youth face particular sociocultural and 
structural barriers to accessing sexual and reproductive 
health services including poor health literacy, stigma, 
shame, judgmental attitudes of health-care providers, and 
the need for guardian consent. Globally health facility 
usage rates among youth remain low.6 Most participants 
stated they would access a clinic if they developed STI 
symptoms, but this may reflect their familiarity with a 
clinic setting. Only a minority favoured educational 
institutions for STI service delivery due to concerns about 
confidentiality, a finding also raised previously in a study 
of Kenyan female adolescents.19 STI testing in a 
community-based setting was the most commonly 
chosen option by participants. This might be because 
chlamydia or gonorrhoea testing was o!ered as part of an 
integrated package of youth-friendly HIV and sexual and 
reproductive services codesigned with youth to optimise 
accessibility and acceptability. However, given that 
participants were recruited while accessing a community-
based sexual and reproductive service, these results might 
not be representative of youth in the wider community 
and desirability bias may have influenced responses.
Uptake of chlamydia and gonorrhoea testing in 
this study was initially low but increased three-fold 
from 12% to 37% over the 8 month study period. This 
increase is probably due to health-care providers gaining 
more experience and confidence in providing STI services, 
as well as the availability of Information, Education and 
Communication material for participants. Modelling 
studies indicate that uptake is the key factor in determining 
the e!ect of screening programmes on prevalence of 
chlamydia.20 Therefore, increased uptake must be achieved 
and evidence from high-income countries has shown that 
large amounts of e!ort and changes to practice are often 
required to achieve high coverage.8 Although young 
people are regularly exposed to information about HIV 
through school programmes and media campaigns, much 
less attention has been paid to curable STIs.21–23 We found 
low levels of knowledge about STI risks, symptoms, and 
complications, a finding also reported by other studies 
from sub-Saharan Africa.24 This has implications for 
uptake of STI testing as individuals who are asymptomatic 
might not realise they are infected and could decline 
testing. Additionally, only 44% of participants noted 
condom use at last sexual intercourse, showing the need 
to continue emphasising condom use. Having symptoms 
was significantly associated with uptake of STI testing on 
multivariate analysis. However, only a minority of 
participants had symptoms, and being symptomatic was a 
poor predictor for having chlamydia or gonorrhoea. 
Previous studies have shown similar findings, and 
support the use of an unselected approach to STI testing 
that is not dependent on symptoms.4
In addition to a lack of information, prevailing 
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misinfo rmation was a barrier to STI testing. A number 
of participants were unaware of the di!erence between 
HIV and other STIs, and felt protected from other STIs if 
they had been tested for HIV. An additional barrier to 
uptake of testing was fear of a positive test result and 
consequent stigma. Similar results were reported in a 
study of adolescent girls from Kenya.19 These findings 
underscore the importance of providing adequate and 
age-appropriate information to inform decision making 
and counselling to accompany testing.
Combining STI testing with e!ective follow-up 
strategies is crucial to ensure that those diagnosed are 
treated. Despite active and confidential follow-up, a third 
of participants with a positive test were lost to follow-up. 
Only 44% of participants provided correct traceable contact 
details, which might be related to concerns regarding 
confidentiality. However, about half of those with a 
positive test result who were uncontactable, and a similar 
proportion of those with a negative test result, returned to 
collect their result spontaneously, demonstrating their 
interest in their test results.
Partner notification is an important component of STI 
control as treatment of partners can prevent reinfection 
of the index patient, break the cycle of transmission, and 
reduce infection burden.5 The yield of partner notification 
in our study was very low with less than 10% of partners 
attending for treatment. We cannot be certain that some 
partners did not attend alternative facilities for follow-up 
and treatment, but the low rates attending study 
sites indicate the challenges associated with partner 
notification.
A systematic review investigating the acceptability and 
e"cacy of partner notifications in sub-Saharan Africa 
showed that 25% (range 0–77) of partners notified by direct 
patient referral attended services for evaluation or were 
treated. Provider referral (69%) and expedited partner 
treatment (84%) was more successful than direct patient 
referral.25 Patient referral was the most popular method of 
partner notification in our study, but about a third of 
participants also selected provider referral as an option for 
partner notification. Providing multiple options could 
improve the success of partner notification, but is not the 
only consideration. Concerns about being accused of 
infidelity and fear of violence or the relationship ending 
impede individuals from informing their partners,26,27 and 
emphasise the importance of counselling and support for 
both indexes and their partners.
The strengths of the study were the assessment of a 
large number of participants along the whole cascade of 
care from testing to treatment and partner notification, 
the moderate sample size for the regression analyses, the 
o!er of unselected testing and inclusion of men, and the 
use of mixed research methods to investigate the 
facilitators and barriers to chlamydia and gonorrhoea 
testing. The study was done in four urban communities in 
Harare, Zimbabwe, which limits the generalisability of 
our findings. Given the stigma surrounding sex, under-
reporting of sexual activity, particularly on reporting of 
socially proscribed behaviours such as transactional sex, 
might have occurred. We used urine samples, which are 
slightly less sensitive than vaginal swabs.28 Vaginal swabs 
were not available as an option for women who could not 
provide urine samples. Additionally, we did not o!er 
testing for other common genital infections such as 
Trichomonas vaginalis or bacterial vaginosis. Finally, some 
questions on preferences for service delivery were based 
on hypothetical scenarios, which might have a!ected the 
validity of responses. For example, the majority of women 
preferred urine samples but they had no experience of 
vaginal swabs. Studies from sub-Saharan Africa show that 
vaginal swabs are highly acceptable and a systematic 
review from 2015 found that women found vaginal swabs 
marginally more acceptable than urine samples.29
Overall, our study found a high prevalence of chlamydia 
and gonorrhoea among youth who were o!ered un-
selective testing in a community-based setting. Potential 
areas for improvement include the inclusion of rapid 
tests for T vaginalis and bacterial vaginosis, allowing for a 
more comprehensive service. Increased regular testing 
might be required for young people at particularly high 
risk of STIs. Strategies to improve follow-up of 
participants and partner notification are vital to ensure 
treatment of STIs and the interruption of chains of 
transmission. Development of a!ordable point-of-care 
tests for STIs will help to improve rates of treatment 
following diagnosis. As availability of diagnostics 
increases, innovative strategies for delivery of STI testing 
and care that address the barriers to access and uptake 
will need to be developed. The lessons learned from HIV 
testing and treatment programmes such as provision of 
information and counselling and stigma reduction can 
serve as a template for designing STI service models. 
Importantly, given the wide avail ability of HIV services, 
meaningful integration of STI services, and more 
generally sexual and reproductive health services, can 
create synergies by capitalising on existing infrastructure, 
knowledge, and skills.
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